title: A randomized controlled trial of eicosapentaenoic acid and/or aspirin for colorectal adenoma prevention during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme (The seAFOod Polyp Prevention Trial): study protocol for a randomized controlled trial.
abstract: BACKGROUND
  The naturally-occurring omega (ω)-3 polyunsaturated fatty acid (PUFA) eicosapentaenoic acid (EPA) reduces colorectal adenoma (polyp) number and size in patients with familial adenomatous polyposis. The safety profile and potential cardiovascular benefits associated with ω-3 PUFAs make EPA a strong candidate for colorectal cancer (CRC) chemoprevention, alone or in combination with aspirin, which itself has recognized anti-CRC activity. Colorectal adenoma number and size are recognized as biomarkers of future CRC risk and are established as surrogate end-points in CRC chemoprevention trials.
  
  
  METHODS
  The seAFOod Polyp Prevention Trial is a randomized, double-blind, placebo-controlled, 2×2 factorial 'efficacy' study, which will determine whether EPA prevents colorectal adenomas, either alone or in combination with aspirin. Participants are 55-73 year-old patients, who have been identified as 'high risk' (detection of ≥5 small adenomas or ≥3 adenomas with at least one being ≥10 mm in diameter) at screening colonoscopy in the English Bowel Cancer Screening Programme (BCSP). Exclusion criteria include the need for more than one repeat endoscopy within the three-month BCSP screening period, malignant change in an adenoma, regular use of aspirin or non-aspirin non-steroidal anti-inflammatory drugs, regular use of fish oil supplements and concomitant warfarin or anti-platelet agent therapy. Patients are randomized to either EPA-free fatty acid 1 g twice daily or identical placebo AND aspirin 300 mg once daily or identical placebo, for approximately 12 months. The primary end-point is the number of participants with one or more adenomas detected at routine one-year BCSP surveillance colonoscopy. Secondary end-points include the number of adenomas (total and 'advanced') per patient, the location (left versus right colon) of colorectal adenomas and the number of participants re-classified as 'intermediate risk' for future surveillance. Exploratory end-points include levels of bioactive lipid mediators such as ω-3 PUFAs, resolvin E1 and PGE-M in plasma, urine, erythrocytes and rectal mucosa in order to gain insights into the mechanism(s) of action of EPA and aspirin, alone and in combination, as well as to discover predictive biomarkers of chemopreventive efficacy. The recruitment target is 904 patients.
  
  
  BACKGROUND
  Current Controlled Trials ISRCTN05926847.
authors.forename: Mark A
authors.initials: MA
authors.lastname: Hull
authors.forename: Anna C
authors.initials: AC
authors.lastname: Sandell
authors.forename: Alan A
authors.initials: AA
authors.lastname: Montgomery
authors.forename: Richard F A
authors.initials: RF
authors.lastname: Logan
authors.forename: Gayle M
authors.initials: GM
authors.lastname: Clifford
authors.forename: Colin J
authors.initials: CJ
authors.lastname: Rees
authors.forename: Paul M
authors.initials: PM
authors.lastname: Loadman
authors.forename: Diane
authors.initials: D
authors.lastname: Whitham
mesh_terms: D000236:Adenoma / Q000175:diagnosis / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D000368:Aged; D016588:Anticarcinogenic Agents / Q000627:therapeutic use*; D001241:Aspirin / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000378:metabolism; D002985:Clinical Protocols; D003113:Colonoscopy; D015179:Colorectal Neoplasms / Q000175:diagnosis* / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D015118:Eicosapentaenoic Acid / Q000627:therapeutic use*; D004739:England; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D012107:Research Design; D018570:Risk Assessment; D012307:Risk Factors; D018401:Sample Size; D013222:State Medicine; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D016588:Anticarcinogenic Agents; D014408:Biomarkers, Tumor; D015118:Eicosapentaenoic Acid; D001241:Aspirin
references.citation: J Am Coll Cardiol. 2009 Aug 11;54(7):585-94
references.pmid: 19660687
references.citation: Am J Clin Nutr. 2012 Mar;95(3):703-12
references.pmid: 22277551
references.citation: Prostaglandins Other Lipid Mediat. 2011 Nov;96(1-4):27-36
references.pmid: 21864702
references.citation: Am J Gastroenterol. 1999 Jan;94(1):194-9
references.pmid: 9934755
references.citation: Recent Results Cancer Res. 2013;191:143-56
references.pmid: 22893204
references.citation: Gut. 2012 Nov;61(11):1576-82
references.pmid: 22200840
references.citation: Gastroenterology. 2008 Apr;134(4):1224-37
references.pmid: 18395100
references.citation: J Natl Cancer Inst. 2009 Feb 18;101(4):256-66
references.pmid: 19211452
references.citation: N Engl J Med. 2000 Jun 29;342(26):1946-52
references.pmid: 10874062
references.citation: Am J Clin Nutr. 2002 Nov;76(5):1007-15
references.pmid: 12399272
references.citation: Gut. 2010 Jul;59(7):918-25
references.pmid: 20348368
references.citation: Eur J Cancer Prev. 2012 May;21(3):231-40
references.pmid: 22456425
references.citation: Cochrane Database Syst Rev. 2001;(3):CD003205
references.pmid: 11687050
references.citation: Eur J Clin Nutr. 2003 Oct;57(10):1323-30
references.pmid: 14506496
references.citation: JAMA. 2003 May 21;289(19):2545-53
references.pmid: 12759326
references.citation: Clin Cancer Res. 2010 Dec 1;16(23):5703-11
references.pmid: 21030497
references.citation: Curr Pharm Des. 2007;13(22):2274-82
references.pmid: 17692000
references.citation: Gut. 2010 May;59(5):666-89
references.pmid: 20427401
references.citation: Prostaglandins Leukot Essent Fatty Acids. 2012 Oct-Nov;87(4-5):143-51
references.pmid: 23017325
references.citation: Thromb Haemost. 2008 Oct;100(4):634-41
references.pmid: 18841286
references.citation: Curr Opin Cell Biol. 2005 Apr;17(2):174-82
references.pmid: 15780594
references.citation: Lancet. 2010 May 8;375(9726):1624-33
references.pmid: 20430429
references.citation: Best Pract Res Clin Gastroenterol. 2011 Aug;25(4-5):547-54
references.pmid: 22122770
references.citation: Cancer Prev Res (Phila). 2012 Feb;5(2):164-78
references.pmid: 22084361
references.citation: Biochem Biophys Res Commun. 1988 Apr 15;152(1):328-35
references.pmid: 3358766
references.citation: N Engl J Med. 2012 Feb 23;366(8):687-96
references.pmid: 22356322
references.citation: Gut. 2012 Jan;61(1):135-49
references.pmid: 21490374
references.citation: Gut. 2012 Aug;61(8):1172-9
references.pmid: 21997545